English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 45422/58598 (78%)
造訪人次 : 2528931      線上人數 : 187
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/61401


    題名: 將分散之真實世界數據應用於臨床性研究:以OHDSI為例
    The Application of Distributed Real-World Data on Clinical Research: Taking OHDSI as an Example
    作者: 王暄翔
    WANG, HSUAN-HSIANG
    貢獻者: 智慧數據應用產業碩士專班
    許明暉
    關鍵詞: 真實世界數據;真實世界證據;臨床性研究
    Real-World Data;Real-World Evidence;Clinical Research
    日期: 2021-07-07
    上傳時間: 2022-03-03 11:30:23 (UTC+8)
    摘要: 在2016年12月13日,時任美國總統歐巴馬簽署了『21世紀醫療法案』(21st Century Cures Act)的最終版本,這個法案中,有個重要的部分影響了現今的臨床試驗方式,就是修改了FDA在臨床試驗上的核准程序,放寬新藥物、醫療產品的認證過程所需的證據資料與數據,允許以「真實世界證據」作為一部分的臨床試驗資料。FDA的決策使得藥廠與研究單位因不需要再另外準備傳統臨床試驗之對照組,而加速了許多藥物、醫療方法的臨床試驗進度,在面對缺乏足夠患者的情況,如罕見疾病藥物的研發更是如此。而這一決策除了應用在罕見疾病上,在近年最嚴重的全球規模傳染病中,我們也看到了「真實世界證據」的價值。

    本研究藉由蒐集到的學術文獻、技術文件與法律相關文件,歸納真實世界證據的重要性、與如何將真實世界數據轉化處理成真實世界證據,並舉出在實行時可能面對的困難。

    本研究試著去探討我國在將「真實世界證據」應用臨床試驗上,是否有可以比照美國FDA現行應用模式的可行性,透過基於OHDSI這一觀察性數據交換平台所倡議的通用資料模型(CDM),本研究試著將國內醫療院所建立的真實世界數據轉換成該格式,並藉由實作資料轉換過程的經驗與所發現的問題點,試著進行研究檢討。
    On December 13, 2016, US President Obama signed into law the 21st Century Cures Act. One of the important section impact the current clinical trial design, which is the amendments of trial approval process; accelerates drug and medical device development; accepts『the real-word data』as part of clinical trial data. Additional Control-Group no longer required for some trials initiated by pharmaceutical companies and research institute, which promotes and funds the acceleration of research into preventing and curing serious illnesses. The improvement of orphan drugs and serious global-scale anti-infection drugs research shown the value of real -world data adoption.

    We collected academic literature, technical documents, and related legal documents, confirm the importance of real-world evidence, and investigate how to transform real-world data into real-world evidence, and cites the difficulties that may be faced in implementation.
    Our research attempt to explore the possibility to adopt US FDA's『the real-word data』modules for our local trials. We transform the real data provided by local medical-care institute through OHDSI data exchange platform to their format, also find and discuss the issues we have during the study.
    描述: 碩士
    指導教授:許明暉
    委員:徐之昇
    委員:顏如娟
    資料類型: thesis
    顯示於類別:[大數據科技及管理研究所] 博碩士論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML566檢視/開啟


    在TMUIR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    著作權聲明 Copyright Notice
    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏,包含體系內各式學術著作及學術產出。秉持開放取用的精神,提供使用者進行資料檢索、下載與取用,惟仍請適度、合理地於合法範圍內使用本平台之內容,以尊重著作權人之權益。商業上之利用,請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台,視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例,並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者,煩請權利人通知本平台維護人員([email protected]),將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋